What Do the FDA Regulations Governing Disclosure of Individual COIs Require?

The answer

The FDA regulations on individual conflicts of interest—found in 21 CFR Part 54, "Financial Disclosure by Clinical Investigators"—require the applicant (the company submitting a marketing application for a drug, biologic, or medical device) to either certify the absence of specified financial interests of its clinical investigators or disclose those interests to the FDA. In other words, the obligation is triggered at the point of marketing application submission, and it falls on the sponsor/applicant, not directly on the investigator.

If an application does not include the required certification or disclosure—or a statement of due diligence showing the applicant tried to obtain the information—the FDA may refuse to file the application. This is the enforcement lever that makes the rule meaningful.

What must be disclosed

The covered financial interests are specific dollar-threshold and outcome-dependent arrangements that could bias a clinical study, including:

• Compensation tied to the study outcome (payments whose value depends on the trial results).
• Significant equity interest in the sponsor—for a publicly traded company, ownership exceeding a set dollar threshold; for a non-public company, any equity interest.
• Proprietary interests in the tested product, such as a patent, trademark, copyright, or licensing agreement.
• Significant payments of other sorts from the sponsor (e.g., grants, honoraria, consulting) above a set threshold beyond the cost of conducting the study.

The applicant collects this information from investigators and reports it to the FDA so reviewers can weigh whether financial bias may have affected the study data.

Why this differs from PHS/investigator rules

Students often confuse the FDA rule with the PHS (Public Health Service) financial conflict-of-interest regulations (42 CFR Part 50). They are different:

• FDA (21 CFR 54): Applies to applicants submitting marketing applications. Disclosure is made to the FDA, at the time of application. The focus is the integrity of the submitted clinical data.
• PHS (42 CFR 50): Applies to investigators on PHS-funded research. Investigators disclose significant financial interests to their institution, which then manages, reduces, or eliminates the conflict and reports to the funding agency. The focus is managing bias in federally funded research.

So the FDA framework is application- and applicant-centered, while the PHS framework is investigator- and institution-centered. Answer choices that say investigators must report to their institution, or that describe ongoing management plans, describe the PHS rule, not the FDA rule.

The bigger picture

The purpose of 21 CFR Part 54 is to protect the reliability of clinical trial data used to approve products for the market. By forcing applicants to reveal investigators' financial ties, the FDA can scrutinize studies where bias is plausible and, if needed, request additional analyses or audits. Knowing that the duty attaches to the applicant at marketing-application submission—and that missing disclosures can block filing—is the key to answering CITI questions on this topic correctly.